S100A8/S100A9 expression was associated with activated p53 and TLR4 signaling in mesenchymal cells and it predicted leukemic evolution in a cohort of homogeneously treated low-risk MDS patients. This evidence concerns the gene S100A8 and myelodysplastic syndrome.